Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a…
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study…
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in…
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center,…
By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…